ChiCTR2200065426 版本V1.3 版本创建时间2025/04/30 17:43:28 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200065426 

最近更新日期:

Date of Last Refreshed on:

2023-04-26 12:09:12 

注册时间:

Date of Registration:

2022-11-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

早期乳腺癌腔镜辅助对比开放下保留乳头乳晕皮下腺体切除+I期假体重建术的多中心前瞻性队列临床研究

Public title:

A multicenter prospective cohort clinical study of endoscope-assisted comparative open nipple-preserving areola subcutaneous adenectomy plus stage I prosthesis reconstruction in early breast cancer

注册题目简写:

乳腺癌腔镜下皮下腺体切除多中心前瞻性队列研究

English Acronym:

A multicenter prospective cohort study of endoscopic subcutaneous adenectomy for breast cancer

研究课题的正式科学名称:

早期乳腺癌腔镜辅助对比开放下保留乳头乳晕皮下腺体切除+I期假体重建术的多中心前瞻性队列临床研究

Scientific title:

A multicenter prospective cohort clinical study of endoscope-assisted comparative open nipple-preserving areola subcutaneous adenectomy plus stage I prosthesis reconstruction in early breast cancer

研究课题代号(代码):

Study subject ID:

(A)KY2022121

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

(A)KY2022121

申请注册联系人:

胡滢 

研究负责人:

姜军 

Applicant:

Hu Ying 

Study leader:

Jiang Jun 

申请注册联系人电话:

Applicant telephone:

+86 15215048081

研究负责人电话:

Study leader's
telephone:

+86 13508319495

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

totoyingying@hotmail.com.cn

研究负责人电子邮件:

Study leader's E-mail:

jcbd@medmail.com.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陆军军医大学第一附属医院(西南医院)乳腺甲状腺外科,重庆市沙坪坝区高滩岩正街30号

研究负责人通讯地址:

陆军军医大学第一附属医院(西南医院)乳腺甲状腺外科,重庆市沙坪坝区高滩岩正街30号

Applicant address:

Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Army Military Medical University (Southwest Hospital), 30 Gaotanyan Main Street, Shapingba District, Chongqing

Study leader's address:

Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Army Military Medical University (Southwest Hospital), 30 Gaotanyan Main Street, Shapingba District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

陆军军医大学第一附属医院(西南医院)乳腺甲状腺外科

Applicant's institution:

Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Army Military Medical University (Southwest Hospital)

研究负责人所在单位:

陆军军医大学第一附属医院(西南医院)乳腺甲状腺外科

Affiliation of the Leader:

Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Army Military Medical University (Southwest Hospital)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(A)KY2022121

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军陆军军医大学第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Army Medical University, PLA

伦理委员会批准日期:

Date of approved by ethic committee:

2022-09-28 00:00:00

伦理委员会联系人:

中国人民解放军陆军军医大学第一附属医院伦理委员会,刘蕾

Contact Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Army Medical University, PLA; Liu Lei

伦理委员会联系地址:

中国人民解放军陆军军医大学第一附属医院,重庆市沙坪坝区高滩岩正街30号

Contact Address of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Army Medical University, 30 Gaotanyan Main Street, Shapingba District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

023-68754035

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xnyyec@sina.com

研究实施负责(组长)单位:

陆军军医大学第一附属医院(西南医院)乳腺甲状腺外科

Primary sponsor:

Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Army Military Medical University (Southwest Hospital)

研究实施负责(组长)单位地址:

陆军军医大学第一附属医院(西南医院)乳腺甲状腺外科,重庆市沙坪坝区高滩岩正街30号

Primary sponsor's address:

Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Army Military Medical University (Southwest Hospital), 30 Gaotanyan Main Street, Shapingba District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

沙坪坝区

Country:

China

Province:

Chongqing

City:

Shapingba District

单位(医院):

陆军军医大学第一附属医院(西南医院)乳腺甲状腺外科

具体地址:

高滩岩正街30号

Institution
hospital:

Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Army Military Medical University (Southwest Hospital)

Address:

30 Gaotanyan Main Street

经费或物资来源:

无经费或物资来源

Source(s) of funding:

No source of funds or materials

研究疾病:

乳腺癌  

Target disease:

Breast cancer

研究疾病代码:

2D10-2D1Z

Target disease code:

2D10-2D1Z

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

以开放手术为对照,评价腔镜辅助保留乳头乳晕皮下腺体切除+I期假体重建术治疗早期乳腺癌的疗效和手术安全性。  

Objectives of Study:

Compared with open surgery, the efficacy and safety of endoscope-assisted nipple-areola subcutaneous adenectomy and stage I false weight reconstruction in the treatment of early breast cancer were evaluated.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18岁-70岁;
2.病理证实为浸润性乳腺癌;
3.T1-2N0M0不愿意保乳或T3N0M0经新辅助治疗后仍不适合行保乳手术;
4.乳房体积小于500 ml,无重度下垂者;
5.肿瘤未侵及乳头乳晕及皮下组织;
6.术前ECOG体力状态评分0~1分;
7.术前ASA评分I-III;
8.接受乳腺假体重建,同意参加本研究并签署知情同意书。

Inclusion criteria

1. Aged 18-70 years;
2. Pathologically confirmed invasive breast cancer;
3. T1-2N0M0 is unwilling to conserve breast or T3N0M0 is still not suitable for breast conserving surgery after neoadjuvant therapy;
4. Breast volume is smaller than 500ml, no severe prolapse;
5. Tumor does not invade nipple areola and subcutaneous tissue;
6. Preoperative ECOG physical status score 0.1;
7. Preoperative ASA score I-III.
8. Accept breast prosthesis reconstruction, agree to participate in this study and sign informed consent form.

排除标准:

1.双侧乳腺癌或对侧乳房需要行预防性切除;
2.术后需行放疗;
3.入组之前接受过不规范的抗肿瘤综合治疗;
4.严重心、肝、肺、肾等重要脏器功能障碍不能耐受麻醉手术及必需的综合治疗;
5.恶性肿瘤病史,或检查发现合并其它恶性肿瘤(甲状腺癌、皮肤基底细胞癌等除外);
6.长期吸烟史;
7.严重的精神疾患;
8.6个月内有不稳定性心绞痛或心肌梗塞史、脑梗塞或脑出血病史;
9.需要进行其他疾病的同期大手术治疗;
10.怀孕和哺乳期妇女。

Exclusion criteria:

1. Prophylactic mastectomy is required for bilateral breast cancer or contralateral breast;
2. Postoperative radiotherapy is required;
3. Before entering the group, they have received irregular anti-tumor therapy;
4. Severe heart, liver, lung, kidney and other important organ dysfunction can not tolerate anesthetic surgery and necessary comprehensive treatment;
5. History of malignant tumor, or examination found to be complicated with other malignant tumors (except thyroid carcinoma, skin basal cell carcinoma, etc.);
6. Long-term smoking history;
7. Severe mental illness;
8. History of unstable angina pectoris or myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months;
9. Simultaneous major surgery for other diseases;
10. Pregnant and lactating women.

研究实施时间:

Study execute time:

From 2022-11-01 00:00:00 To 2028-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-11-14 00:00:00 To 2023-04-14 00:00:00

干预措施:

Interventions:

组别:

研究组

样本量:

439

Group:

Research Group

Sample size:

干预措施:

腔镜辅助

干预措施代码:

Intervention:

Endoscopic assistance

Intervention code:

组别:

对照组

样本量:

1317

Group:

control group

Sample size:

干预措施:

传统开放手术

干预措施代码:

Intervention:

Traditional open surgery

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆市 

市(区县):

沙坪坝区 

Country:

China

Province:

Chongqing

City:

Shapingba District

单位(医院):

陆军军医大学第一附属医院(西南医院)乳腺甲状腺外科 

单位级别:

三级甲等 

Institution
hospital:

Department of Breast and Thyroid Surgery, the First Affiliated Hospital of Army Military Medical University (Southwest Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后美容效果(乳房满意度)

指标类型:

主要指标

Outcome:

Postoperative cosmetic effect (breast satisfaction)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

无标本

组织:

无组织

Sample Name:

No specimen

Tissue:

No tissue

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

未随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Not randomly grouped

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

病例记录表实时共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Real-time sharing of Case Record Form

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-11-04 12:54:43